Physician profile
Joehar Hamdan
NPI 1508062159
$6,761.68
in general payments reported to CMS, 2019-2025
63 companies · $1,230 in 2025
The $1,230 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $811 · 2020: $772 · 2021: $725 · 2022: $820 · 2023: $1,250 · 2024: $1,153 · 2025: $1,230.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,282 · Education: $351.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,282.21 |
| Education | $350.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $511.43 | 2021-2025 | |
| Pfizer INC. | $430.71 | 2019-2025 | |
| Janssen Biotech, INC. | $419.01 | 2019-2025 | Rybrevant, Darzalex, Talvey |
| Lilly USA, LLC | $392.35 | 2019-2024 | Retevmo, Verzenio, Jaypirca |
| E.R. Squibb & Sons, L.L.C. | $373.37 | 2019-2025 | Opdivo, Opdualag, Eliquis |
| Astrazeneca Pharmaceuticals LP | $295.95 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Celgene Corporation | $276.10 | 2020-2025 | Reblozyl, Pomalyst, Opdualag |
| Genentech USA, INC. | $264.16 | 2019-2025 | Polivy, Avastin, Tecentriq |
| Astellas Pharma US INC | $239.83 | 2021-2025 | Padcev, Xtandi |
| Merck Sharp & Dohme LLC | $237.87 | 2019-2025 | Keytruda, Welireg |
| Eisai INC. | $221.65 | 2019-2025 | |
| Abbvie INC. | $209.87 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $198.95 | 2020-2023 | |
| Gilead Sciences, INC. | $192.38 | 2021-2025 | Trodelvy |
| Pharmacyclics LLC, An Abbvie Company | $168.35 | 2020-2023 | Imbruvica |
Show all 63 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $146.65 | 2019-2023 | Jakafi |
| Takeda Pharmaceuticals U.S.A., INC. | $141.51 | 2023-2025 | Ninlaro, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $116.17 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $112.40 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.34 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $107.80 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Daiichi Sankyo INC. | $103.74 | 2019-2024 | Enhertu |
| Seagen INC. | $93.08 | 2020-2023 | Tukysa |
| Genzyme Corporation | $79.49 | 2020-2024 | |
| Amgen INC. | $79.48 | 2019-2023 | Lumakras |
| Exelixis INC. | $72.76 | 2019-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $71.37 | 2020-2024 | Ojjaara, Zejula, Jemperli |
| Rigel Pharmaceuticals, INC. | $66.92 | 2020-2022 | |
| G1 Therapeutics, INC. | $64.47 | 2022-2023 | Cosela |
| Adc Therapeutics America, INC. | $60.98 | 2022-2024 | |
| Azurity Pharmaceuticals, INC. | $49.70 | 2025 | Danziten, Vivimusta |
| Pharmacosmos Therapeutics INC. | $49.01 | 2022-2024 | Cosela |
| Sumitomo Pharma America, INC. | $44.54 | 2023-2024 | Orgovyx |
| Myriad Genetic Laboratories, INC. | $43.44 | 2021-2022 | |
| Exact Sciences Corporation | $40.47 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Aveo Pharmaceuticals, INC. | $39.97 | 2023-2024 | Fotivda |
| Mirati Therapeutics, INC. | $39.02 | 2023-2024 | Krazati |
| Karyopharm Therapeutics INC. | $38.64 | 2020-2021 | |
| Epizyme, INC. | $38.09 | 2022 | |
| Alexion Pharmaceuticals, INC. | $36.85 | 2019-2025 | Ultomiris |
| Inspire Medical Systems, INC. | $35.43 | 2024 | Inspire |
| Regeneron Healthcare Solutions, INC. | $30.72 | 2024 | Libtayo |
| Idorsia Pharmaceuticals US INC | $30.69 | 2022-2023 | Quviviq |
| Medtronic USA, INC. | $25.36 | 2019 | |
| Pharmaessentia USA Corporation | $24.09 | 2025 | Besremi |
| Novocure INC. | $23.69 | 2025 | Optune Lua (Novottf-200t) |
| Sobi, INC | $23.02 | 2025 | |
| Array Biopharma INC | $22.20 | 2025 | Tukysa, Braftovi, Mektovi |
| Taiho Oncology, INC. | $21.14 | 2023 | |
| Tersera Therapeutics LLC | $21.11 | 2025 | Zoladex |
| Myovant Sciences INC. | $19.42 | 2021 | |
| Jazz Pharmaceuticals INC. | $19.36 | 2021 | |
| Tesaro, INC. | $19.24 | 2019 | |
| Eusa Pharma (US) LLC | $19.15 | 2021 | |
| Kite Pharma, INC. | $18.84 | 2020 | |
| Beone Medicines USA, INC. | $18.47 | 2025 | Brukinsa |
| Intera Oncology, INC | $17.71 | 2025 | Intera |
| Global Blood Therapeutics, INC. | $17.69 | 2022 | |
| Dendreon Pharmaceuticals LLC | $17.53 | 2019 | |
| Immunomedics, INC. | $16.05 | 2020 | |
| Advanced Accelerator Applications | $15.36 | 2019 | |
| Verastem, INC. | $12.47 | 2019 | |
| Kyowa Kirin, INC. | $12.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joehar Hamdan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.